echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > China NMPA receives the NDA of Envafolimab (KN035) for the treatment of MSI-H/dMMR advanced solid tumors

    China NMPA receives the NDA of Envafolimab (KN035) for the treatment of MSI-H/dMMR advanced solid tumors

    • Last Update: 2021-01-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Biopharmaceutical company TRACON announced today that China's State Drug Administration (NMPA) has accepted a new drug application (NDA) from Envafolimab (KN035) for the treatment of MSI-H/dMMR advanced solid tumors.
    Charles Theuer, chief executive of TRACON, said: "Envafolimab's NDA has been reviewed by Chinese regulators, highlighting Envafolimab's advanced nature.
    In addition to the registered trial of MSI-H/dMMR advanced solid tumors in China, Envafolimab is in the process of two other registration trials, one in China for stage III of bile daema cancer and the other for sarcoma in the United States."
    Envafolimab (KN035) is a new monolith antibody for PD-L1.
    microsatellite (MS) refers to a series of repeated DNA sequences in the cell genome in the units of a few nucleotides (mostly 1 to 6).
    an abnormality in the DNA Misaling Repair (MMR) function, replication errors in microsatellites are not corrected and accumulate, resulting in changes in the length or base composition of microsatellite sequences, known as microsatellite instability (MSI).
    clinical treatment needs of patients with microsatellite highly unstable (MSI-H)/mismatch repair defect (dMMR) solid tumors have not been met.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.